Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

RUTI Vaccination Enhances Inhibition of Mycobacterial Growth ex vivo and Induces a Shift of Monocyte Phenotype in Mice.

Prabowo SA, Painter H, Zelmer A, Smith SG, Seifert K, Amat M, Cardona PJ, Fletcher HA.

Front Immunol. 2019 Apr 30;10:894. doi: 10.3389/fimmu.2019.00894. eCollection 2019.

2.

How Far Are we Away From an Improved Vaccine For Tuberculosis? Current Efforts and Future Prospects.

Vilaplana C, Cardona PJ.

Arch Bronconeumol. 2018 Dec 26. pii: S0300-2896(18)30446-0. doi: 10.1016/j.arbres.2018.11.002. [Epub ahead of print] Review. English, Spanish.

3.

The burden of disease in Spain: Results from the Global Burden of Disease 2016.

Soriano JB, Rojas-Rueda D, Alonso J, Antó JM, Cardona PJ, Fernández E, Garcia-Basteiro AL, Benavides FG, Glenn SD, Krish V, Lazarus JV, Martínez-Raga J, Masana MF, Nieuwenhuijsen MJ, Ortiz A, Sánchez-Niño MD, Serrano-Blanco A, Tortajada-Girbés M, Tyrovolas S, Haro JM, Naghavi M, Murray CJL; Colaboradores de GBD en España; Lista de colaboradores de GBD en España:.

Med Clin (Barc). 2018 Sep 14;151(5):171-190. doi: 10.1016/j.medcli.2018.05.011. Epub 2018 Jul 20. English, Spanish.

4.

A Beneficial Effect of Low-Dose Aspirin in a Murine Model of Active Tuberculosis.

Kroesen VM, Rodríguez-Martínez P, García E, Rosales Y, Díaz J, Martín-Céspedes M, Tapia G, Sarrias MR, Cardona PJ, Vilaplana C.

Front Immunol. 2018 Apr 23;9:798. doi: 10.3389/fimmu.2018.00798. eCollection 2018.

5.

A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis.

Leung-Theung-Long S, Coupet CA, Gouanvic M, Schmitt D, Ray A, Hoffmann C, Schultz H, Tyagi S, Soni H, Converse PJ, Arias L, Kleinpeter P, Sansas B, Mdluli K, Vilaplana C, Cardona PJ, Nuermberger E, Marchand JB, Silvestre N, Inchauspé G.

PLoS One. 2018 May 2;13(5):e0196815. doi: 10.1371/journal.pone.0196815. eCollection 2018.

6.

High Antigen Dose Is Detrimental to Post-Exposure Vaccine Protection against Tuberculosis.

Billeskov R, Lindenstrøm T, Woodworth J, Vilaplana C, Cardona PJ, Cassidy JP, Mortensen R, Agger EM, Andersen P.

Front Immunol. 2018 Jan 15;8:1973. doi: 10.3389/fimmu.2017.01973. eCollection 2017.

7.

Pathogenesis of tuberculosis and other mycobacteriosis.

Cardona PJ.

Enferm Infecc Microbiol Clin. 2018 Jan;36(1):38-46. doi: 10.1016/j.eimc.2017.10.015. Epub 2017 Dec 2. English, Spanish.

PMID:
29198784
8.

What We Have Learned and What We Have Missed in Tuberculosis Pathophysiology for a New Vaccine Design: Searching for the "Pink Swan".

Cardona PJ.

Front Immunol. 2017 May 15;8:556. doi: 10.3389/fimmu.2017.00556. eCollection 2017. Review.

9.

Pilot, double-blind, randomized, placebo-controlled clinical trial of the supplement food Nyaditum resae® in adults with or without latent TB infection: Safety and immunogenicity.

Montané E, Barriocanal AM, Arellano AL, Valderrama A, Sanz Y, Perez-Alvarez N, Cardona P, Vilaplana C, Cardona PJ.

PLoS One. 2017 Feb 9;12(2):e0171294. doi: 10.1371/journal.pone.0171294. eCollection 2017.

10.

Experimental animal modelling for TB vaccine development.

Cardona PJ, Williams A.

Int J Infect Dis. 2017 Mar;56:268-273. doi: 10.1016/j.ijid.2017.01.030. Epub 2017 Feb 3. Review.

11.

Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif.

Molinos-Albert LM, Bilbao E, Agulló L, Marfil S, García E, Rodríguez de la Concepción ML, Izquierdo-Useros N, Vilaplana C, Nieto-Garai JA, Contreras FX, Floor M, Cardona PJ, Martinez-Picado J, Clotet B, Villà-Freixa J, Lorizate M, Carrillo J, Blanco J.

Sci Rep. 2017 Jan 13;7:40800. doi: 10.1038/srep40800.

12.

Development of the food supplement Nyaditum resae as a new tool to reduce the risk of tuberculosis development.

Tukvadze N, Cardona P, Vashakidze S, Shubladze N, Avaliani Z, Vilaplana C, Cardona PJ.

Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S101-S102. doi: 10.1016/j.ijmyco.2016.09.073. Epub 2016 Nov 14.

13.

Retrospective study of clinical and lesion characteristics of patients undergoing surgical treatment for Pulmonary Tuberculosis in Georgia.

Vashakidze S, Despuig A, Gogishvili S, Nikolaishvili K, Shubladze N, Avaliani Z, Tukvadze N, Casals M, Caylà JA, Cardona PJ, Vilaplana C.

Int J Infect Dis. 2017 Mar;56:200-207. doi: 10.1016/j.ijid.2016.12.009. Epub 2016 Dec 19. Review.

14.

Reactivation or reinfection in adult tuberculosis: Is that the question?

Cardona PJ.

Int J Mycobacteriol. 2016 Dec;5(4):400-407. doi: 10.1016/j.ijmyco.2016.09.017. Epub 2016 Oct 27. Review.

15.

The Progress of Therapeutic Vaccination with Regard to Tuberculosis.

Cardona PJ.

Front Microbiol. 2016 Sep 28;7:1536. eCollection 2016. Review.

17.

Local Inflammation, Dissemination and Coalescence of Lesions Are Key for the Progression toward Active Tuberculosis: The Bubble Model.

Prats C, Vilaplana C, Valls J, Marzo E, Cardona PJ, López D.

Front Microbiol. 2016 Feb 2;7:33. doi: 10.3389/fmicb.2016.00033. eCollection 2016.

18.

Individual-Based Modeling of Tuberculosis in a User-Friendly Interface: Understanding the Epidemiological Role of Population Heterogeneity in a City.

Prats C, Montañola-Sales C, Gilabert-Navarro JF, Valls J, Casanovas-Garcia J, Vilaplana C, Cardona PJ, López D.

Front Microbiol. 2016 Jan 12;6:1564. doi: 10.3389/fmicb.2015.01564. eCollection 2015.

19.

Oral Administration of Heat-Killed Mycobacterium manresensis Delays Progression toward Active Tuberculosis in C3HeB/FeJ Mice.

Cardona P, Marzo-Escartín E, Tapia G, Díaz J, García V, Varela I, Vilaplana C, Cardona PJ.

Front Microbiol. 2016 Jan 5;6:1482. doi: 10.3389/fmicb.2015.01482. eCollection 2015.

20.

Towards host-directed therapies for tuberculosis.

Zumla A, Maeurer M; Host-Directed Therapies Network, Chakaya J, Hoelscher M, Ntoumi F, Rustomjee R, Vilaplana C, Yeboah-Manu D, Rasolof V, Munderi P, Singh N, Aklillu E, Padayatchi N, Macete E, Kapata N, Mulenga M, Kibiki G, Mfinanga S, Nyirenda T, Maboko L, Garcia-Basteiro A, Rakotosamimanana N, Bates M, Mwaba P, Reither K, Gagneux S, Edwards S, Mfinanga E, Abdulla S, Cardona PJ, Russell JB, Gant V, Noursadeghi M, Elkington P, Bonnet M, Menendez C, Dieye TN, Diarra B, Maiga A, Aseffa A, Parida S, Wejse C, Petersen E, Kaleebu P, Oliver M, Craig G, Corrah T, Tientcheu L, Antonio M, Rao M, McHugh TD, Sheikh A, Ippolito G, Ramjee G, Kaufmann SH, Churchyard G, Steyn A, Grobusch M, Sanne I, Martinson N, Madansein R, Wilkinson RJ, Mayosi B, Schito M, Wallis RS.

Nat Rev Drug Discov. 2015 Aug;14(8):511-2. doi: 10.1038/nrd4696. Epub 2015 Jul 17.

PMID:
26184493
21.

The key role of exudative lesions and their encapsulation: lessons learned from the pathology of human pulmonary tuberculosis.

Cardona PJ.

Front Microbiol. 2015 Jun 16;6:612. doi: 10.3389/fmicb.2015.00612. eCollection 2015. Review.

22.

Draft Genome Sequences of Mycobacterium setense Type Strain DSM-45070 and the Nonpathogenic Strain Manresensis, Isolated from the Bank of the Cardener River in Manresa, Catalonia, Spain.

Rech G, Vilaplana C, Velasco J, Pluvinet R, Santín S, Prat C, Julián E, Alcaide F, Comas I, Sumoy L, Cardona PJ.

Genome Announc. 2015 Feb 5;3(1). pii: e01485-14. doi: 10.1128/genomeA.01485-14.

23.

Deletion of zmp1 improves Mycobacterium bovis BCG-mediated protection in a guinea pig model of tuberculosis.

Sander P, Clark S, Petrera A, Vilaplana C, Meuli M, Selchow P, Zelmer A, Mohanan D, Andreu N, Rayner E, Dal Molin M, Bancroft GJ, Johansen P, Cardona PJ, Williams A, Böttger EC.

Vaccine. 2015 Mar 10;33(11):1353-9. doi: 10.1016/j.vaccine.2015.01.058. Epub 2015 Feb 2.

PMID:
25657094
24.

To achieve an earlier IFN-γ response is not sufficient to control Mycobacterium tuberculosis infection in mice.

Vilaplana C, Prats C, Marzo E, Barril C, Vegué M, Diaz J, Valls J, López D, Cardona PJ.

PLoS One. 2014 Jun 24;9(6):e100830. doi: 10.1371/journal.pone.0100830. eCollection 2014.

25.

Multiple consecutive infections might explain the lack of protection by BCG.

Cardona PJ, Vilaplana C.

PLoS One. 2014 Apr 16;9(4):e94736. doi: 10.1371/journal.pone.0094736. eCollection 2014.

26.

Therapeutic vaccines for tuberculosis--a systematic review.

Gröschel MI, Prabowo SA, Cardona PJ, Stanford JL, van der Werf TS.

Vaccine. 2014 May 30;32(26):3162-8. doi: 10.1016/j.vaccine.2014.03.047. Epub 2014 Apr 13. Review.

PMID:
24726245
28.

Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection.

Nell AS, D'lom E, Bouic P, Sabaté M, Bosser R, Picas J, Amat M, Churchyard G, Cardona PJ.

PLoS One. 2014 Feb 26;9(2):e89612. doi: 10.1371/journal.pone.0089612. eCollection 2014.

29.

Damaging role of neutrophilic infiltration in a mouse model of progressive tuberculosis.

Marzo E, Vilaplana C, Tapia G, Diaz J, Garcia V, Cardona PJ.

Tuberculosis (Edinb). 2014 Jan;94(1):55-64. doi: 10.1016/j.tube.2013.09.004. Epub 2013 Sep 19.

PMID:
24291066
30.

The scavenger protein apoptosis inhibitor of macrophages (AIM) potentiates the antimicrobial response against Mycobacterium tuberculosis by enhancing autophagy.

Sanjurjo L, Amézaga N, Vilaplana C, Cáceres N, Marzo E, Valeri M, Cardona PJ, Sarrias MR.

PLoS One. 2013 Nov 4;8(11):e79670. doi: 10.1371/journal.pone.0079670. eCollection 2013.

31.

Evolution and role of corded cell aggregation in Mycobacterium tuberculosis cultures.

Caceres N, Vilaplana C, Prats C, Marzo E, Llopis I, Valls J, Lopez D, Cardona PJ.

Tuberculosis (Edinb). 2013 Nov;93(6):690-8. doi: 10.1016/j.tube.2013.08.003. Epub 2013 Aug 13.

PMID:
24011631
32.

Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials.

Arbues A, Aguilo JI, Gonzalo-Asensio J, Marinova D, Uranga S, Puentes E, Fernandez C, Parra A, Cardona PJ, Vilaplana C, Ausina V, Williams A, Clark S, Malaga W, Guilhot C, Gicquel B, Martin C.

Vaccine. 2013 Oct 1;31(42):4867-73. doi: 10.1016/j.vaccine.2013.07.051. Epub 2013 Aug 17.

PMID:
23965219
33.

Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis.

Vilaplana C, Marzo E, Tapia G, Diaz J, Garcia V, Cardona PJ.

J Infect Dis. 2013 Jul 15;208(2):199-202. doi: 10.1093/infdis/jit152. Epub 2013 Apr 5.

PMID:
23564636
34.

Chemo-enzymatic synthesis and glycosidase inhibitory properties of DAB and LAB derivatives.

Concia AL, Gómez L, Bujons J, Parella T, Vilaplana C, Cardona PJ, Joglar J, Clapés P.

Org Biomol Chem. 2013 Mar 28;11(12):2005-21. doi: 10.1039/c3ob27343a. Epub 2013 Feb 5.

PMID:
23381224
35.

Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines.

Prabowo SA, Gröschel MI, Schmidt ED, Skrahina A, Mihaescu T, Hastürk S, Mitrofanov R, Pimkina E, Visontai I, de Jong B, Stanford JL, Cardona PJ, Kaufmann SH, van der Werf TS.

Med Microbiol Immunol. 2013 Apr;202(2):95-104. doi: 10.1007/s00430-012-0278-6. Epub 2012 Nov 10. Review.

PMID:
23143437
36.

Chemoenzymatic synthesis, structural study and biological activity of novel indolizidine and quinolizidine iminocyclitols.

Gómez L, Garrabou X, Joglar J, Bujons J, Parella T, Vilaplana C, Cardona PJ, Clapés P.

Org Biomol Chem. 2012 Aug 21;10(31):6309-21. doi: 10.1039/c2ob25943e. Epub 2012 Jun 26.

PMID:
22735612
37.

Low dose aerosol fitness at the innate phase of murine infection better predicts virulence amongst clinical strains of Mycobacterium tuberculosis.

Caceres N, Llopis I, Marzo E, Prats C, Vilaplana C, de Viedma DG, Samper S, Lopez D, Cardona PJ.

PLoS One. 2012;7(1):e29010. doi: 10.1371/journal.pone.0029010. Epub 2012 Jan 3.

38.

Experimental model of tuberculosis in the domestic goat after endobronchial infection with Mycobacterium caprae.

de Val Pérez B, López-Soria S, Nofrarías M, Martín M, Vordermeier HM, Villarreal-Ramos B, Romera N, Escobar M, Solanes D, Cardona PJ, Domingo M.

Clin Vaccine Immunol. 2011 Nov;18(11):1872-81. doi: 10.1128/CVI.05323-11. Epub 2011 Aug 31.

39.

Prophylactic effect of a therapeutic vaccine against TB based on fragments of Mycobacterium tuberculosis.

Vilaplana C, Gil O, Cáceres N, Pinto S, Díaz J, Cardona PJ.

PLoS One. 2011;6(5):e20404. doi: 10.1371/journal.pone.0020404. Epub 2011 May 24.

40.

Newborn mice vaccination with BCG.HIVA²²² + MVA.HIVA enhances HIV-1-specific immune responses: influence of age and immunization routes.

Saubi N, Im EJ, Fernández-Lloris R, Gil O, Cardona PJ, Gatell JM, Hanke T, Joseph J.

Clin Dev Immunol. 2011;2011:516219. doi: 10.1155/2011/516219. Epub 2011 Apr 12.

41.

The secret trumps, impelling the pathogenicity of tubercle bacilli.

Cardona PJ, Ivanyi J.

Enferm Infecc Microbiol Clin. 2011 Mar;29 Suppl 1:14-9. doi: 10.1016/S0213-005X(11)70013-1. Review. Erratum in: Enferm Infecc Microbiol Clin. 2012 Mar;30(3):172.

PMID:
21420562
42.

A spotlight on liquefaction: evidence from clinical settings and experimental models in tuberculosis.

Cardona PJ.

Clin Dev Immunol. 2011;2011:868246. doi: 10.1155/2011/868246. Epub 2011 Mar 13. Review.

43.

A multistage tuberculosis vaccine that confers efficient protection before and after exposure.

Aagaard C, Hoang T, Dietrich J, Cardona PJ, Izzo A, Dolganov G, Schoolnik GK, Cassidy JP, Billeskov R, Andersen P.

Nat Med. 2011 Feb;17(2):189-94. doi: 10.1038/nm.2285. Epub 2011 Jan 23.

PMID:
21258338
44.

[Immunodiagnosis and biomarkers in tuberculosis].

Guio H, Vilaplana C, Cardona PJ.

Med Clin (Barc). 2011 Oct 8;137(9):408-13. doi: 10.1016/j.medcli.2010.09.008. Epub 2010 Nov 5. Review. Spanish.

PMID:
21056436
45.

Mathematical modeling of tuberculosis bacillary counts and cellular populations in the organs of infected mice.

Bru A, Cardona PJ.

PLoS One. 2010 Sep 23;5(9):e12985. doi: 10.1371/journal.pone.0012985.

46.

Molecular characterization of heterologous HIV-1gp120 gene expression disruption in mycobacterium bovis BCG host strain: a critical issue for engineering mycobacterial based-vaccine vectors.

Joseph J, Fernández-Lloris R, Pezzat E, Saubi N, Cardona PJ, Mothe B, Gatell JM.

J Biomed Biotechnol. 2010;2010:357370. doi: 10.1155/2010/357370. Epub 2010 Jun 27.

47.

Granuloma encapsulation is a key factor for containing tuberculosis infection in minipigs.

Gil O, Díaz I, Vilaplana C, Tapia G, Díaz J, Fort M, Cáceres N, Pinto S, Caylà J, Corner L, Domingo M, Cardona PJ.

PLoS One. 2010 Apr 6;5(4):e10030. doi: 10.1371/journal.pone.0010030.

48.

Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis.

Rullas J, García JI, Beltrán M, Cardona PJ, Cáceres N, García-Bustos JF, Angulo-Barturen I.

Antimicrob Agents Chemother. 2010 May;54(5):2262-4. doi: 10.1128/AAC.01423-09. Epub 2010 Feb 16.

50.

Tuberculin immunotherapy: its history and lessons to be learned.

Vilaplana C, Cardona PJ.

Microbes Infect. 2010 Feb;12(2):99-105. doi: 10.1016/j.micinf.2009.10.006. Epub 2009 Nov 4.

PMID:
19895902

Supplemental Content

Loading ...
Support Center